Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jumpvax: Delta-inulin Adjuvant in Jack Jumper Ant Venom Immunotherapy
NCT03066986Phase 2Unknown
- Sponsor
- Central Adelaide Local Health Network
- Start
- Oct 2016
- Primary completion
- Dec 2021
- Modality
- Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of delta inulin in Jack Jumper ant venom allergy (JJAVA), sponsored by Central Adelaide Local Health Network. Status: unknown.
02
Drugs
delta inulin
03
Conditions
Jack Jumper ant venom allergy (JJAVA)
Beyond the preview
Go deeper on NCT03066986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03066986.